VivoSeq
Immunology

Allergy

108

Pipeline Programs↗

20

Active Trials↗

29

Companies Involved↗

Allergy is a highly competitive landscape with 108 programs across 29 companies. The most active players are COUR Pharmaceutical Development Company, Inc., Astellas, Pfizer. 19 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

22/100

Mech. Concentration

27/100

Completion Rate

84/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

COUR Pharmaceutical Development Company, Inc.

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1K

Kenvue Brands

1 program

Phase 1C

Coronado Biosciences, Inc.

1 program

Phase 1A

Allergy Therapeutics

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical20

Amoxicillin

Global Antibiotics Research and Development Partnership

Olopatadine

Novartis

Allergen Specific Immunotherapy

University of Zurich

Beclomethasone

Chiesi Farmaceutici S.p.A.

BAY987517

Bayer

Phase 112

Dapsone

Almirall, S.A.

Inhaled Epinephrine

Dr. George Luciuk

CNP-201

COUR Pharmaceutical Development Company, Inc.

ASP4070

Astellas

Cetirizine

Kenvue Brands

Phase 248

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

DUPIXENT

Regeneron

Epinephrine

Samson Clinical Operations Pty Ltd

Antihistamine

Arrowhead Pharmaceuticals

Omalizumab

Roche

Phase 39

Fluticasone Propionate

GSK

Desloratadine

Organon and Co

Ligelizumab

Novartis

AR101

Aimmune Therapeutics, Inc.

REGN1909

Regeneron

Approved19

Loratadine

Perrigo Company

Esomeprazole

Dexcel Pharma Technologies Ltd.

Metronidazole

DePuy Orthopaedics

Clarithromycin

AbbVie

Bismuth Potassium Citrate

Mission Pharmacal

Analysis

Modality Breakdown

93%

Small molecule

90 of 97 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody44%Vaccine22%Protein / enzyme11%

Small molecule leads; the ring shows all 97 classified programs, each share of the total. Modality classified for 100% of 150 pipeline programs.

Analysis

Trial Status

159

clinical trials

Completed108 · 68%
Recruiting14 · 9%
Terminated12 · 8%
Unknown status10 · 6%
Withdrawn9 · 6%
Enrolling by invitation3 · 2%
Other3 · 2%

Clinical Trials

Trial Activity

159 trials

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
Recruiting·—·Phase 3·NCT04898283·180 enrolled
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges
Recruiting·—·Phase 1·NCT07038746·100 enrolled
Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.
Recruiting·—·N/A·NCT06790368·80 enrolled
Geisinger Antibiotic Allergy Pilot Program: Assess and Address
Recruiting·GGeisinger Clinic·Phase 1·NCT05464615·100 enrolled
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Recruiting·MMassachusetts General Hospital·Phase 2·NCT06406114·300 enrolled
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
Recruiting·AALK-Abelló A/S·Phase 3·NCT07060885·300 enrolled
Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge
Recruiting·JJames Tarbox, MD·Phase 3·NCT06303128·380 enrolled
Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study
Recruiting·PPablo Rodríguez del Rio·Phase 2/3·NCT06976775·40 enrolled
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Recruiting·—·Phase 3·NCT04891237·180 enrolled
Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy
Recruiting·—·N/A·NCT06782217·120 enrolled
Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children
Recruiting·LLaure Pittet, MD-PhD·Phase 4·NCT05758532·500 enrolled
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
Recruiting·—·Phase 3·NCT04435990·150 enrolled
Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma
Recruiting·UUniversity of Zurich·Phase 1/2·NCT06960382·36 enrolled
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Recruiting·MMabylon AG·Phase 1·NCT07287033·48 enrolled
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Active, not recruiting·AAravax Pty Ltd·Phase 2·NCT05621317·90 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)